WallStSmart

Medtronic PLC (MDT)vsStryker Corporation (SYK)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Medtronic PLC generates 41% more annual revenue ($35.48B vs $25.12B). MDT leads profitability with a 13.0% profit margin vs 12.9%. SYK appears more attractively valued with a PEG of 1.38. SYK earns a higher WallStSmart Score of 67/100 (B-).

MDT

Buy

56

out of 100

Grade: C

Growth: 4.0Profit: 6.5Value: 7.3Quality: 5.0

SYK

Strong Buy

67

out of 100

Grade: B-

Growth: 8.0Profit: 7.5Value: 8.7Quality: 7.0
Piotroski: 3/9Altman Z: 2.18
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

MDTSignificantly Overvalued (-254.0%)

Margin of Safety

-254.0%

Fair Value

$24.34

Current Price

$86.16

$61.82 premium

UndervaluedFair: $24.34Overvalued
SYKUndervalued (+13.5%)

Margin of Safety

+13.5%

Fair Value

$392.65

Current Price

$335.67

$56.98 discount

UndervaluedFair: $392.65Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

MDT4 strengths · Avg: 8.3/10
Market CapQuality
$113.55B9/10

Large-cap with strong market position

Price/BookValuation
2.3x8/10

Reasonable price relative to book value

Operating MarginProfitability
20.0%8/10

Strong operational efficiency at 20.0%

Free Cash FlowQuality
$2.30B8/10

Generating 2.3B in free cash flow

SYK4 strengths · Avg: 8.8/10
EPS GrowthGrowth
55.9%10/10

Earnings expanding 55.9% YoY

Market CapQuality
$133.77B9/10

Large-cap with strong market position

Operating MarginProfitability
27.2%8/10

Strong operational efficiency at 27.2%

Free Cash FlowQuality
$1.88B8/10

Generating 1.9B in free cash flow

Areas to Watch

MDT2 concerns · Avg: 3.0/10
PEG RatioValuation
1.554/10

Expensive relative to growth rate

EPS GrowthGrowth
-11.8%2/10

Earnings declined 11.8%

SYK2 concerns · Avg: 2.5/10
Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

P/E RatioValuation
41.7x2/10

Premium valuation, high expectations priced in

Comparative Analysis Report

WallStSmart Research

Bull Case : MDT

The strongest argument for MDT centers on Market Cap, Price/Book, Operating Margin.

Bull Case : SYK

The strongest argument for SYK centers on EPS Growth, Market Cap, Operating Margin. Revenue growth of 11.4% demonstrates continued momentum. PEG of 1.38 suggests the stock is reasonably priced for its growth.

Bear Case : MDT

The primary concerns for MDT are PEG Ratio, EPS Growth.

Bear Case : SYK

The primary concerns for SYK are Piotroski F-Score, P/E Ratio. A P/E of 41.7x leaves little room for execution misses.

Key Dynamics to Monitor

SYK carries more volatility with a beta of 0.87 — expect wider price swings.

SYK is growing revenue faster at 11.4% — sustainability is the question.

MDT generates stronger free cash flow (2.3B), providing more financial flexibility.

Monitor MEDICAL DEVICES industry trends, competitive dynamics, and regulatory changes.

Bottom Line

SYK scores higher overall (67/100 vs 56/100) and 11.4% revenue growth. Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Medtronic PLC

HEALTHCARE · MEDICAL DEVICES · USA

Medtronic plc is an American-Irish registered medical device company that primarily operates in the United States. Medtronic has an operational and executive headquarters in Fridley, Minnesota in the US.

Stryker Corporation

HEALTHCARE · MEDICAL DEVICES · USA

Stryker Corporation is an American multinational medical technologies corporation based in Kalamazoo, Michigan. Stryker's products include implants used in joint replacement and trauma surgeries; surgical equipment and surgical navigation systems; endoscopic and communications systems; patient handling and emergency medical equipment; neurosurgical, neurovascular and spinal devices; as well as other medical device products used in a variety of medical specialties.

Visit Website →

Want to dig deeper into these stocks?